Novo Nordisk receives a positive opinion from the CHMP for a label update of Wegovy to reflect reduced heart failure symptoms ...

The company said at its capital markets day in March that it expected that weight loss could reach 15%, on par with its ...

Novo Nordisk's shares fell nearly 5% on Friday after results from a Phase 2a trial of the Danish drugmaker's experimental obesity pill monlunabant came in below market expectations.

Novo Nordisk has multiple, strong upcoming, positive catalysts, related to its GLP-1 weight-loss drugs, Ozempic and Wegovy.

U.S. telehealth company Hims & Hers Health on Wednesday said it will sell compounded versions of Novo Nordisk's popular ...

Eli Lilly and Novo Nordisk the pharmaceutical heavyweights selling popular weight-loss injections are each dangling discounts to gain an edge and to ...

Novo Nordisk's stock dropped by more than 4% following disappointing results from a Phase 2a trial of its obesity pill, Monlunabant. The experimental drug, acquired through Inversago Pharmaceuticals, ...

Dr. Andrew Wheeler said anyone considering medications like Wegovy or Ozempic should be ready to commit to taking them ...

Ozempic is patented to treat type 2 diabetes, improving blood sugar to reduce the risk of major cardiovascular incidents. The ...

For patients on a 12-month plan, Hims offers a semaglutide injection for $199 a month. Ozempic and Wegovy carry high list prices of $935.77 and $1,349.02, respectively, for a month’s supply, according ...

Ozempic can therefore also lead to weight loss, as the drug also reduces appetite, as well as delaying the rate at which food ...

Hims & Hers Health will offer compounded GLP-1 weight-loss medications for as low as $99 per month to eligible U.S. military ...